Business
Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo
New Analyses from Three Trials in Obstructive HCM Support Findings from Previously Published Data on MYQORZO™ (aficamten) SOUTH SAN FRANCISCO, Calif., March
About this update from Cytokinetics, Incorporated
[{"type":"text","content":"New Analyses from Three Trials in Obstructive HCM Support Findings from Previously Published Data on MYQORZO™ (aficamten) SOUTH SAN FRANCISCO, Calif., March 16, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced four presentations related to MYQORZO™ (aficamten) at the American College of Cardiology (ACC) Annual Scientific Session & Expo taking place March 28–30, 2026 in New Orleans, LA. Recently approved for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) by the U.S. Food and Drug Administration, European Commission, and the China National Medical Products Administration, MYQORZO is an allosteric and reversible inhibitor of cardiac myosin motor activity. In patients with oHCM, myosin inhibition with MYQORZO reduces cardiac contractility and consequently, left ventricular outflow tract (LVOT) obstruction. “We are pleased to contribute further evidence that we believe will help physicians and patients with clinical decision making,” said Stephen Heitner, M.D., Senior Vice President, Clinical Research and Development. “The new data can help empower evidence-based choices of therapy for patients living with symptomatic oHCM, showing that aficamten improves exercise capacity, when compared to placebo or the beta blocker, metoprolol, while maintaining its safety profile.” Scientific Presentations Include: Evaluation of Aficamten or Beta-Blocker Monotherapy Versus Placebo in Patients with Obstructive Hypertrophic Cardiomyopathy: A Pooled Analysis of SEQUOIA-HCM and MAPLE-HCM (1186-09)Moderated Poster Presentation, March 30,2026, 11:00 AM-12:00 PM CT, E Hall P. Christian Schulze, M.D., Ph.D., Chair of the Department of Medicine and Division of Cardiology, Angiology and Intensive Medical Care at the University Hospital Jena A new analysis based on combined data from SEQUOIA-HCM (Safety, Efficacy, and Quantitative Understanding of Obstruction Impact of Aficamten in HCM) and MAPLE-HCM (Metoprolol vs Aficamten in Patients with LVOT Obstruction on Exercise Capacity in HCM) evaluated aficamten or metoprolol monotherapy versus placebo. Patients (n=371) were pooled into three groups: aficamten as monotherapy, metoprolol as monotherapy, and placebo without background beta-blockers. For patients with symptomatic oHCM, treatment with beta-blocker monotherapy was no different ...